Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;17(10):1029-1037.
doi: 10.1111/ddg.13964.

Dermatological complications of therapy with biologics in inflammatory autoimmune diseases

Wiebke Sondermann  1 , Saskia Herz  1 , Elsa Sody  1 , Andreas Körber  2
Affiliations

Dermatological complications of therapy with biologics in inflammatory autoimmune diseases

Wiebke Sondermann et al. J Dtsch Dermatol Ges. 2019 Oct.

Abstract

Background and objective: Cutaneous adverse events (CAEs) occur in up to 10 % of patients with immune-mediated inflammatory disease (IMID) treated with antitumor necrosis factor (TNF)α agents. The aim of this clinical study was to track and observe the course of CAEs in all biologic therapies.

Patients and methods: The population for this study consisted of patients with CAEs under biologic therapy who were examined by experienced board-certified dermatologists in the outpatient department of the University Hospital Essen, Department of Dermatology.

Results: Altogether 39 patients with a total of 45 CAEs were included in this study. In 60 % of the cases a form of paradoxical psoriasis was diagnosed. Two thirds (66.6 %) of the patients with CAEs were diagnosed with an underlying inflammatory bowel disease (IBD). TNFα antagonists were the triggering agents in about 95 % of the cases. Changes in biological therapy were required in nearly half of the cases (46.2 %). Almost 90 % of the patients had either a complete (42.1 %) or a partial response (47 %).

Conclusions: Management of CEAs under biological therapy can be challenging in clinical practice. Case discussions between gastroenterologists, rheumatologists and dermatologists should be undertaken to best manage patients with CAEs and avoid unnecessary changes of therapy.

PubMed Disclaimer

References

    1. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40(3): 233-40.
    1. Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018; 16 (5): 645-69.
    1. Moran GW, Lim AW, Bailey JL et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38 (9): 1002-24.
    1. Weisenseel P, Reich K. Paradoxical skin reactions under therapy with TNF-alpha antagonists. Z Rheumatol 2013; 72 (5): 423-8.
    1. Navarro R, Dauden E. Clinical management of paradoxical psoriasiform reactions during TNF-alpha therapy. Actas Dermosifiliogr 2014; 105 (8): 752-61.

MeSH terms

Substances

LinkOut - more resources